2024/11/07 19:36:58 | |
---|---|
Price | |
194.76 USD | |
Difference | 5.85% (10.76) |
ISIN | BE0003739530 |
Symbol | UCB |
Exchange | FINRA other OTC Issues |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 34,662 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 194.76 USD |
High | 194.76 USD |
Low | 194.76 USD |
Close (prev. day) | 184.00 USD |
VWAP | 194.76 USD |
Volume (pcs) | 1,061 |
Trading volume | 206,640.36 |
Number of trades | 1 |
Last size | 1,061 |
Related Futures | 23 |
Related Options | - |
Date | Headline | Download | |
2024/11/05 | Global Equity Ratings | ||
2024/10/29 | Global Equity Ratings | ||
2024/10/22 | Global Equity Ratings | ||
2024/09/27 | Global Equity Ratings | ||
2024/09/11 | Global Equity Ratings |
2024/11/07 19:36:58 | |
---|---|
Price | |
194.76 USD | |
Difference | 5.85% (10.76) |
ISIN | BE0003739530 |
Symbol | UCB |
Exchange | FINRA other OTC Issues |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 34,662 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 194.76 USD |
High | 194.76 USD |
Low | 194.76 USD |
Close (prev. day) | 184.00 USD |
VWAP | 194.76 USD |
Volume (pcs) | 1,061 |
Trading volume | 206,640.36 |
Number of trades | 1 |
Last size | 1,061 |
6m | 1Y | 3Y | |
Perf (%) | - | +163.19% | - |
Perf (abs.) | - | +120.76 | - |
Beta | 0.79 | 0.83 | 0.67 |
Volatility | 6.93 | 11.11 | 18.71 |
Ø price 5 days | Ø volume 5 days (pcs.) | - USD (-) |
Ø price 30 days | Ø volume 30 days (pcs.) | 189.38 USD (89) |
Ø price 100 days | Ø volume 100 days (pcs.) | 172.59 USD (393) |
Ø price 250 days | Ø volume 250 days (pcs.) | 132.76 USD (236) |
YTD High | date | 194.76 USD (2024/11/07) |
YTD Low | date | 100.00 USD (2024/02/09) |
52 Weeks High | date | 194.76 USD (2024/11/07) |
52 Weeks Low | date | 69.70 USD (2023/11/09) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Vienna Stock Exchange | 2024/11/13 | 15:30 | 181.95 EUR | 0.00 | 4 |
Tradegate | 2024/11/13 | 22:26 | 181.65 EUR | 0.11 | 26 |
Stuttgart | 2024/11/14 | 08:10 | 180.45 EUR | 0.00 | 1 |
Munich | 2024/11/14 | 08:00 | 180.20 EUR | 0.00 | 1 |
London Stock Exchange European Trade Reporting | 2024/11/13 | 17:30 | 182.125 EUR | 0.00 | 2 |
Frankfurt | 2024/11/14 | 08:07 | 181.35 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/11/07 | 19:36 | 194.76 USD | 0.21 | 1 |
Euronext Milan MTF Trading After Hours | - | - | - | 0.00 | - |
Euronext Brussels | 2024/11/13 | 17:39 | 182.70 EUR | 40.25 | 3,607 |
Duesseldorf | 2024/11/14 | 08:10 | 179.80 EUR | 0.00 | 1 |
Berlin | 2024/11/14 | 08:03 | 181.55 EUR | 0.00 | 1 |
UCB SA |
- - |
Allée de la Recherche, 60 - 1070 Brüssel |
Telefon: +32-2-559-99-99 |
Fax: + |
E-mail: contactucb@ucb.com |
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium. |
Jean-Christophe Tellier | Chairman of Managing Board |
Alistair Henry | Member of Executive Committee |
Denelle Waynick Johnson | Member of Executive Committee |
Emmanuel Caeymaex | Member of Executive Committee |
Fiona du Monceau | Member of Executive Committee |
Iris Löw-Friedrich | Member of Executive Committee |
Jean Luc Fleurial | Member of Executive Committee |
Kirsten Lund-Jurgensen | Member of Executive Committee |
Sandrine Dufour | Member of Executive Committee |
Jonathan Peacock | Chairman of Supervisory Board |
Dame Davies | Member of Supervisory Board |
Dolca Thomas | Member of Supervisory Board |
Jan Berger | Member of Supervisory Board |
Susan Gasser | Member of Supervisory Board |
Charles-Antoine Janssen | Member of Supervisory Board |
Cyril Janssen | Member of Supervisory Board |
Jonkheer Cédric van Rijckevorsel | Member of Supervisory Board |
Maëlys Castella | Member of Supervisory Board |
Nefertiti Greene | Member of Supervisory Board |
Pierre Gurdjian | Member of Supervisory Board |
Rodolfo Savitzky | Member of Supervisory Board |
Ulf Arne Wiinberg | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer